AUMED, a.s. Received Support for the Project “PhageBiome-N – Development of an innovative phage and probiotic formulation for the elimination of Staphylococcus aureus strains, including MRSA, and stabilization of the nasal microbiome for use in infection prevention and treatment.”

AUMED, a.s. is launching a project titled PhageBiome-N, which has received support under the Operational Programme Technologies and Applications for Competitiveness 2021–2027, Applications – DEEP TECH – Call III, registration number CZ.01.01.01/01/24_063/0006738.

The aim of the research is to create an innovative product that combines the power of polyvalent phages and selected probiotic strains. This project addresses an urgent need in modern medicine to tackle decolonization and the treatment of upper respiratory tract infections caused by resistant staphylococcal strains, with a specific focus on high-risk MRSA strains.

The primary driver for developing this formulation is the alarming rise of antibiotic resistance. Staphylococcus aureus represents a global challenge, as it is a frequent cause of serious nosocomial (hospital-acquired) infections that complicate hospitalizations and can lead to life-threatening conditions such as septic shock or pneumonia. While asymptomatic nasal carriage is common, it poses a significant risk to immunocompromised patients and nursing staff. Our project aims to eliminate these “superbugs” using natural bacterial viruses—phages—which act selectively and effectively even where conventional antibiotics fail.

The innovation of the product lies in its dual-phase and synergistic action:

• Phase 1: Phage therapy is utilized for the targeted elimination of pathogenic bacteria without disrupting the surrounding microflora.
• Phase 2: Specifically selected probiotic strains (Streptococcus salivarius) stabilize the nasal microbiome, support the natural mucosal barrier, and prevent pathogen recolonization.

This comprehensive approach to human microbiome modulation represents a new generation of biological therapeutics, which currently has no equivalent on the European Union market.

During the research phase, we will focus on identifying the most suitable dosage form for local application. Two variants will be tested: a powder spray based on natural carriers and a nasal insert in lyophilized form. Both delivery methods are designed to ensure maximum stability of the biological components and user comfort.

The product will find application in hospital, outpatient, and individual care as both a preventive and therapeutic measure.